Search research articles
Contact Us
Filters
Showing results (191-200 of 272) with videos related to
Page
of 28
Sort By:
Clinical Rheumatology
|
June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology
|
March 16, 2021
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases
|
July 5, 2022
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, et al.
RMD Open
|
April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
Arthritis Research & Therapy
|
November 13, 2024
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, et al.
The Journal of Rheumatology
|
August 1, 2024
Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease
Daniela Kampel Stolnicki, Laura C Coates, Charlotte E Gollins, et al.
Arthritis Research & Therapy
|
April 10, 2023
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
Xenofon Baraliakos, Roberto Ranza, Andrew Östör, et al.
Rheumatology and Therapy
|
December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
Atul Deodhar, Philip Mease, Proton Rahman, et al.
ACR Open Rheumatology
|
October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study
Philip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 9, 2020
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial
John D Reveille, Atul Deodhar, Akgun Ince, et al.
Page
of 28
Search research articles
Search
Showing results (191-200 of 272) with videos related to
Sort By:
Page
of 28
Clinical Rheumatology
|
June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology
|
March 16, 2021
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases
|
July 5, 2022
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, et al.
RMD Open
|
April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
Arthritis Research & Therapy
|
November 13, 2024
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, et al.
The Journal of Rheumatology
|
August 1, 2024
Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease
Daniela Kampel Stolnicki, Laura C Coates, Charlotte E Gollins, et al.
Arthritis Research & Therapy
|
April 10, 2023
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
Xenofon Baraliakos, Roberto Ranza, Andrew Östör, et al.
Rheumatology and Therapy
|
December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
Atul Deodhar, Philip Mease, Proton Rahman, et al.
ACR Open Rheumatology
|
October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study
Philip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 9, 2020
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial
John D Reveille, Atul Deodhar, Akgun Ince, et al.
Page
of 28